Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Tranylcypromine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 14/20 | 0.75 |
| ▸ | MAOA known ✓ | P21397 | 12/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 13/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.75 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.75 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Tranylcypromine SCHEMBL40650 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL5075069 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL4332273 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL31133533 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL5070768 | 0.98 | KDM4E (0.96) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL3406205 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL40651 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL1649712 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL34339 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A | |
| (+)-Tranylcypromine SCHEMBL13785162 | 0.87 | KDM1A (1.00) | KDM4EMAPTHPGDMAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3961073-A | 2-PHENYL-CYCLOPROPYLAMINE | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1976-06-01 | — | — | US | claimed |
| EP-3617181-A1 | SYNTHESIS OF TRANS-2-PHENYLCYCLOPROPYLAMINE OR A SALT OR SOLVATE THEREOF | Arevipharma GmbH (DE) | 2020-03-04 | — | — | EP | disclosed |
| EP-3617181-A1 | SYNTHESIS OF TRANS-2-PHENYLCYCLOPROPYLAMINE OR A SALT OR SOLVATE THEREOF | Arevipharma GmbH (DE) | 2020-03-04 | — | — | EP | disclosed |
| EP-1758600-A4 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MAN SCIENCES LLC (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070264358-A1 | Methods and Compositions for Treating Mood Disorder | MOOD MANAGEMENT SCIENCES, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070212428-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MANAGEMENT SCIENCES, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| EP-1758600-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | Mood Management Sciences, LLC (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005120523-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MANAGEMENT SCIENCES, LLC (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20040106681-A1 | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders | CYPRESS BIOSCIENCE, INC. | 2004-06-03 | — | — | US | disclosed |
| US-4156017-A | TO PROTECT CROPS FROM CABBAGE MOTH AND BUTTERFLY AND COTTON MOTH; OVICIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 1979-05-22 | — | — | US | disclosed |
| US-4016204-A | ISOMERIZING ETHYL-2-PHENYL-CYCLOPROPANE CARBOXYLATE | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106681-A1 | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders | GABRE, CYP2D6, DDO | MAOB 84/4885MAOA 32/4885KDM4E 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.